CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Companyâ€™s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Companyâ€™s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Employees

Sector

Pharmaceuticals

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

02/06	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
15/05	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	26.48L 23.02L 21.42L 19.67L 37.14L 25Cr 37.72L 2.53Cr 99.1L 13Cr 99.43L 97.25L 42Cr	P/E 2024	-1.11x	P/E 2025	-0.33x
Enterprise Value	2.45Cr 2.13Cr 1.98Cr 1.82Cr 3.44Cr 233.89Cr 3.49Cr 23Cr 9.17Cr 116.44Cr 9.2Cr 9Cr 390.45Cr	EV / Sales 2024	1.75x	EV / Sales 2025	1.9x
Free-Float	53.62%	Yield 2024 *	-	Yield 2025	-

02/06	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
15/05	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
15/05	CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
21/04	CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP	CI
21/04	CASI Pharmaceuticals, Inc. Announces Termination of Dr. Alexander A. Zukiwski, MD as Global Chief Medical Officer, Effective April 20, 2026	CI
03/03	CASI Pharmaceuticals, Inc. Announces CEO Changes	CI
03/03	Casi Pharmaceuticals, Inc. Announces Resignation of Director David Cory, Effective March 31, 2026	CI

Manager	Title	Age	Since
David Cory CEO	Chief Executive Officer	62	21/07/2025
Kun Qian DFI	Director of Finance/CFO	44	16/05/2025
Chun Hua Wang COO	Chief Operating Officer	54	01/01/2017

Director	Title	Age	Since
Yue Wu BRD	Director/Board Member	62	01/04/2013
Zhen Bo Su BRD	Director/Board Member	50	21/03/2023
Thomas Folinsbee BRD	Director/Board Member	59	21/03/2023

ENTREMED Share Price Nasdaq

Stocks

Pharmaceuticals

Valuation: ENTREMED

Latest news : ENTREMED

Press Releases: ENTREMED

Managers and Directors: ENTREMED

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-0.53%	-3.95%	+50.70%	+152.78%	1,02400Cr
JOHNSON & JOHNSON	+0.21%	-2.68%	+53.20%	+50.87%	62TCr
ABBVIE INC.	-2.51%	-3.25%	+28.54%	+67.99%	44TCr
ROCHE HOLDING AG	+0.06%	-0.42%	+37.53%	+31.06%	35TCr
ASTRAZENECA PLC	-0.69%	-0.30%	+13.76%	+12.83%	26TCr
NOVO NORDISK A/S	-7.37%	-4.40%	-0.74%	-43.66%	21TCr
AMGEN INC.	-0.64%	+2.43%	+29.74%	+67.16%	21TCr
GILEAD SCIENCES, INC.	-0.82%	+0.70%	+15.05%	+72.05%	16TCr
PFIZER INC.	+0.40%	+1.92%	+6.47%	-29.25%	14TCr
Average	-1.32%	-1.21%	+26.03%	+42.43%	37.99TCr
Weighted average by Cap.	-1.00%	-2.02%	+36.14%	+71.56%

	2024	2025
Net sales	2.85Cr 2.48Cr 2.31Cr 2.12Cr 4Cr 272.42Cr 4.07Cr 27Cr 11Cr 135.62Cr 11Cr 10Cr 454.76Cr	2.07Cr 1.8Cr 1.68Cr 1.54Cr 2.91Cr 197.72Cr 2.95Cr 20Cr 7.75Cr 98Cr 7.78Cr 7.61Cr 330.06Cr
Net income	-3.93Cr -3.41Cr -3.18Cr -2.92Cr -5.51Cr -374.76Cr -5.59Cr -37Cr -15Cr -186.57Cr -15Cr -14Cr -625.6Cr	-4.81Cr -4.18Cr -3.89Cr -3.57Cr -6.74Cr -458.76Cr -6.85Cr -46Cr -18Cr -228.39Cr -18Cr -18Cr -765.84Cr
Net Debt	60.5L 52.59L 48.95L 44.94L 84.87L 58Cr 86.19L 5.77Cr 2.26Cr 29Cr 2.27Cr 2.22Cr 96Cr	2.19Cr 1.9Cr 1.77Cr 1.62Cr 3.07Cr 208.62Cr 3.11Cr 21Cr 8.18Cr 103.86Cr 8.21Cr 8.03Cr 348.26Cr

End-of-day quote Nasdaq Other stock markets
- ^USD	-